Parathyroid Carcinoma
📧 Sign up to get email alerts when something new happens for Parathyroid Carcinoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: Agnostic Therapy in Rare Solid Tumors [Phase 2]
A Phase 2 trial of an agnostic therapy for multiple rare solid tumors is currently recruiting. The study lists a broad set of tumor types ac…
-
CLINICAL_TRIALS research · 2026-04-14Clinical Trial Update: Radiofrequency Ablation For Recurrent Parathyroid Carcinoma [NA]
Clinical trials.gov indicates a study evaluating radiofrequency ablation for recurrent parathyroid carcinoma is currently recruiting.
-
CLINICAL_TRIALS research · 2026-04-09Clinical Trial Update: Natural History Study of Parathyroid Disorders
This clinical trial update describes a natural history study of parathyroid disorders that is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2025-12-15Clinical Trial Update: Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Parathyroidectomy [NA]
This completed clinical trial evaluates near-infrared autofluorescence for identifying parathyroid glands during parathyroidectomy, with res…
-
CLINICAL_TRIALS research · 2025-11-21Clinical Trial Update: Molecular and Immunohistochemical Profiling of Tumors in Patients With Parathyroid Tumors
A clinical trial entry describing a study that profiles parathyroid tumors using molecular and immunohistochemical techniques.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-08-27Clinical Trial Update: Evaluating Impact of Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Parathyroidectomy [NA]
The clinical trial evaluating near-infrared autofluorescence to identify parathyroid glands during parathyroidectomy has completed, and resu…
-
CLINICAL_TRIALS research · 2025-02-28Clinical Trial Update: PET-TC in Thyroid Evaluation
Clinical trial update indicating that PET-CT is being explored for thyroid evaluation in patients with medullary thyroid carcinoma and parat…
-
CLINICAL_TRIALS research · 2025-01-22Clinical Trial Update: Institution of an Italian Multicenter Database of Patients with Parathyroid Carcinoma or Atypical Parathyroid Adenoma
An Italian multicenter database is being established to collect data on patients with parathyroid carcinoma or atypical parathyroid adenoma,…
-
CLINICAL_TRIALS trial_result · 2021-05-27Clinical Trial Update: Phase 3 Study of KHK7580 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Primary Hyperparathyroidism [Phase 3]
Phase 3 study of KHK7580 for hypercalcemia in parathyroid carcinoma or primary hyperparathyroidism completed; results posted in 2021.
-
FDA approval · 2020-10-07FDA Approved: CINACALCET — Original Application (Camber Pharmaceuticals, Inc.)
The FDA approved Camber Pharmaceuticals' original application for a generic cinacalcet hydrochloride product.
-
FDA approval · 2020-05-18FDA Approved: CINACALCET — Supplemental Application (Strides Pharma Science Limited)
The FDA approved a supplemental application for CINACALCET submitted by Strides Pharma Science Limited under ANDA209226, enabling a suppleme…
-
FDA approval · 2018-03-08FDA Approved: CINACALCET — Original Application (Cipla USA Inc.)
FDA approved Cipla USA Inc.'s generic cinacalcet (cinacalcet) under an original ANDA for its approved indications: secondary hyperparathyroi…
-
FDA approval · 2017-05-23FDA Approved: SENSIPAR — Supplemental Application (Amgen Inc)
FDA approved a supplemental application for Sensipar (cinacalcet hydrochloride) from Amgen Inc, relating to labeling changes for the drug.
-
CLINICAL_TRIALS trial_result · 2017-03-03Clinical Trial Update: An Intra-individual Titration Study of KRN1493 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Intractable Primary Hyperparathyroidism [Phase 3]
Phase 3 intra-individual titration trial evaluating KRN1493 for treating hypercalcemia in patients with parathyroid carcinoma or intractable…
-
FDA approval · 2011-08-01FDA Approved: SENSIPAR — Supplemental Application (Amgen Inc)
The FDA approves a supplemental application for Sensipar (cinacalcet hydrochloride) submitted by Amgen Inc.
-
FDA approval · 2009-11-12FDA Approved: SENSIPAR — Supplemental Application (Amgen Inc)
The FDA approved Amgen's supplemental application for SENSIPAR (cinacalcet hydrochloride), resulting in updated labeling for the product.